Deciphera Pharmaceuticals, LLC

Quick facts

Phase 3 pipeline

• DCC-2618 · Oncology
  DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies.

Phase 1 pipeline

• DCC-2036
• DCC-2812
• DCC-3009

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Deciphera Pharmaceuticals, LLC portfolio CI brief
• Deciphera Pharmaceuticals, LLC pipeline updates RSS